Last reviewed · How we verify

Omaveloxolone Opthalmic Suspension 0.5%

Biogen · Phase 2 active Small molecule

Omaveloxolone Opthalmic Suspension 0.5% is a Small molecule drug developed by Biogen. It is currently in Phase 2 development. Also known as: RTA 408.

At a glance

Generic nameOmaveloxolone Opthalmic Suspension 0.5%
Also known asRTA 408
SponsorBiogen
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Omaveloxolone Opthalmic Suspension 0.5%

What is Omaveloxolone Opthalmic Suspension 0.5%?

Omaveloxolone Opthalmic Suspension 0.5% is a Small molecule drug developed by Biogen.

Who makes Omaveloxolone Opthalmic Suspension 0.5%?

Omaveloxolone Opthalmic Suspension 0.5% is developed by Biogen (see full Biogen pipeline at /company/biogen).

Is Omaveloxolone Opthalmic Suspension 0.5% also known as anything else?

Omaveloxolone Opthalmic Suspension 0.5% is also known as RTA 408.

What development phase is Omaveloxolone Opthalmic Suspension 0.5% in?

Omaveloxolone Opthalmic Suspension 0.5% is in Phase 2.

Related